What the Record Shows: Medical Cannabis and Cannabinoid Research, 1960–1999

MED01 interim technical synthesis — Part 1 of 3

Version: v1.0 — SIGNED OFF by Danny 2026-09-26 · trail: v0.1 Claude → v0.2 ChatGPT calibration (13) + verifier page checks → v1.0 after ChatGPT’s final two corrections (§10 stale HOLD on P6; §11 C017/C018 preparation drift) and one optional precision (§1 integrity-check scope). Remaining HOLD components are open items carried into the plain-English derivatives and the cross-audit; any change is a logged correction. · Ledger basis: MED01 ledger v1.0 (P1 portion, MED01-C001–C040, signed off 2026-09-25) · Evidence search cutoff (MED01-wide): 2026-09-20 · Governing protocol: PROTOCOL-MEDICAL v0.5 · base PROTOCOL v1.4 Standing rule (ChatGPT, R07, carried forward): this synthesis is never more certain, and never simpler, than the ledger. Every substantive sentence carries a claim ID; a reader can go sentence → claim → source → extracted result. Status of this document: interim. It synthesizes P1 (1960–1999) and hands downstream research threads to P2 (2000–2017); P1 remains unlocked pending the plain-English derivatives and the §M10a cross-audit. The final MED01 synthesis is assembled after P3. Components still held for primary-document checks are marked [HOLD] sentence by sentence; the current list is in §12.

This is not medical advice. Everything below describes a research literature and what named studies or bodies reported about the populations they studied, as the evidence stood at the end of 1999 and as located through the 2026-09-20 search cutoff. Nothing here is a statement about what cannabis or any cannabinoid does for a patient today.

1. The question, and how it was answered

The brief asked what the medical and scientific research literature on cannabis and cannabinoids was between 1960 and 1999: who studied what, in which populations, with which preparations and designs, under which legal conditions, and what the syntheses of and about the period concluded. It is an evidence map, not an efficacy review.

Two AI researchers worked independently from the same frozen brief. Neither run was clean — both disclosed that prior project context was visible in their environment, and one retrieved the brief from the shared Drive rather than from an attachment — so agreement between them on the well-known discovery chronology is treated here as convergence on landmarks any model would reach, not as independent confirmation. Where they disagreed, the disagreement was the more informative signal, and the verifier’s checks decided. Every journal citation and identifier in both passes was resolved live against PubMed and Crossref (official documents were checked page by page where reachable, and are marked where not); every quantitative clinical claim was read against the abstract; publication-integrity status was checked on the journal sources with DOIs, where such checks apply (none retracted, corrected, or under concern as of 2026-09-23). Both researchers’ database counts were re-run verbatim. A completeness probe added sources neither had found. Correction rounds were run with both; one researcher’s corrections introduced five new wrong identifiers, each pointing to a paper adjacent to the one intended, and those were caught before anything entered the ledger.

The result is a 40-claim signed ledger, with unresolved components explicitly held rather than inferred through. This synthesis reads it in order.

2. How much was published, and in what shape (C001–C003)

Two frozen PubMed/MEDLINE queries return 8,663 and 10,630 indexed records for 1960–1999 (C001). The absolute number depends on the search string; the shape does not. Both strings show a surge in the 1970s, a trough in the 1980s, and a 1990s peak higher than the 1970s. That replication across strings is the finding worth keeping; the researcher who reported a count of 11,241 with decade percentages to one decimal could not reproduce it, and accepted the verifier’s figure.

The one bibliometric analysis located (Scopus, title search, 1829–2021) puts the United States at 33 records in the 1960s and 979 (41.7%) in the 1970s, the most productive country overall, with NIH, HHS and NIDA prominent among funders (C002). Those are shares of records carrying a US affiliation, not measures of research effort, and the analysis codes countries and funders — not whether a paper studied harms or therapy (see §7).

Read together with the dated discovery and trial record, the period falls into four phases (C003): constituent chemistry in the 1960s; experimental human pharmacology and small therapeutic trials in the 1970s; pharmaceutical cannabinoid development and antiemetic trial programmes in the 1980s; and receptor and endocannabinoid molecular biology, with renewed official review, in the 1990s. The periodization is editorial. The brief asked for natural phases; the boundaries are a reading of the record, not a variable in it.

3. The discoveries that changed what could be asked (C004–C011)

None of the discoveries in this section is human clinical evidence. All are chemistry, molecular biology, or animal pharmacology, and under the protocol they support mechanism and plausibility only.

The decade opened with structure. Cannabidiol’s structure was published in 1963 (C004). Δ9-THC was isolated, its structure assigned and a partial synthesis reported in 1964; the first total synthesis (racemic) followed in 1965, stereospecific and further total syntheses in 1967, and another in 1969 (C005). One researcher dated the first total synthesis to 1967; the indexed record says 1965, and the 1967 paper’s own title says “stereospecific.” Other constituents were characterised through the 1960s and 1970s and a 1980 review catalogued what was then known — the widely repeated figure of 61 cannabinoids in that review is unverified, because no accessible text confirms it (C006). This chemistry enabled dose-defined pharmacology — from 1965 a laboratory could administer a known quantity of a known molecule — but did not itself establish a receptor mechanism.

In 1988, saturable, stereoselective, high-affinity binding of a cannabinoid probe to rat brain membranes (Kd ≈ 133 pM) was characterised (C007). In 1990 a receptor cDNA was cloned and functionally expressed, and receptor distribution was mapped across mammalian brains including human tissue (C008). In 1992 an endogenous ligand, anandamide, was isolated from porcine brain (C009); in 1993 a second receptor, expressed in peripheral immune tissue and not detected in brain, was cloned (C010); in 1995 two groups independently identified 2-arachidonoylglycerol as a second endogenous ligand (C011). By the end of the window the question had moved from “which chemical in cannabis is psychoactive?” to “what does this signalling system do?” — but that question had been answered in molecules, cells and animals, not in patients.

4. What was studied in humans (C012–C021)

The human therapeutic literature of the period is real, small, and product-specific. Many of its keystone trials enrolled tens of patients; the antiemetic programme in particular was dominated by crossover designs (C015); and its endpoints were symptoms measured over hours or a few cycles.

Chemotherapy-induced nausea and vomiting is the period’s clearest clinical programme. In 1975, in a randomized double-blind crossover study of 20 evaluable chemotherapy patients, oral THC produced an antiemetic response in 14 of 20 THC courses and none of 22 placebo courses (C012). In 1979, 15 osteosarcoma patients on high-dose methotrexate had less vomiting and nausea on THC than placebo, with a plasma-concentration gradient; smoked THC was available in that trial as an open-label adjunct, and the study offers no randomized comparison of smoked against oral — a distinction one researcher initially blurred and later conceded (C013). Also in 1979, two crossover trials found nabilone superior to prochlorperazine (80% vs 32% response in 113 patients), with complete relief in only 8% and side effects about twice as frequent — a detail both researchers omitted and the abstract supplies (C014). A 2015 Cochrane reconstruction counts 23 randomized dronabinol or nabilone trials from 1975 to 1991, 19 of them crossovers, most at risk of bias from allocation concealment or attrition; two BMJ systematic reviews in 2001 — one quantitative (antiemesis), one qualitative (pain) — had synthesised the pre-2000 trials earlier, and neither researcher found them (C015).

Cancer pain rests on ten patients: in 1975, single oral doses of 15 and 20 mg THC relieved pain better than placebo, with substantial sedation and mental clouding; the companion codeine comparison called the analgesic effect mild and the 20 mg dose one whose side effects “would prohibit its therapeutic use” (C016). A claimed equivalence to a specific codeine dose is not in either abstract.

Intraocular pressure was first reported to fall after smoking cannabis in a 1971 letter that gives no effect size (C017). The “25–30% reduction” often attached to that letter is not in it, and the replacement sources offered for the figure resolved to unrelated papers. A 1977 study of intravenous THC in ten normotensive subjects reported a mean 37% fall in pressure alongside a 22–65% rise in heart rate; a 1998 review states smoking lowers pressure in 60–65% of users while judging chronic use for glaucoma untenable on systemic grounds. These are physiological endpoints, not glaucoma outcomes.

Bronchodilation was shown acutely: in 1976, one inhalation of 200 µg aerosolised THC improved ventilatory function in ten asthmatic inpatients comparably to salbutamol at one hour; a 1973 NEJM study of smoked cannabis and oral THC in healthy men is identified but carries no abstract, so its result is not stated here (C018). Single doses; nothing about asthma management.

Epilepsy rests on one 1980 Brazilian trial: 15 patients with secondary generalized epilepsy, uncontrolled on their existing drugs, randomized to add-on oral CBD 200–300 mg/day or placebo for up to 4½ months, with 4 of 8 CBD patients reported almost free of seizures, 3 partially improved and 1 unimproved, against 7 of 8 placebo patients unchanged (C019). Spasticity rests on nine: in 1981, 10 mg oral THC reduced clinically measured spasticity versus placebo, and the blinded examiner correctly guessed the THC condition in seven of nine cases (C020). By 1998 the House of Lords could count six published MS trials totalling 41 subjects worldwide (C020; S-286 §5.20, verifier-found).

AIDS-related anorexia produced the period’s largest trial. In 1995, 139 patients (88 evaluable) were randomized to dronabinol 2.5 mg twice daily or placebo; appetite rose 38% versus 8% (P = 0.015) and nausea fell, while mean weight was stable against a 0.4 kg placebo loss — a difference that was not statistically significant (C021). Appetite and weight were different endpoints with different results, and the distinction has to survive into any plain-language version.

5. Preparations, and why they are not one thing (C022–C024)

The period’s human studies used smoked plant material; oral Δ9-THC, later as the pharmaceutical dronabinol; oral purified CBD; the synthetic analogue nabilone; and investigational synthetics — levonantradol, DMHP and dexanabinol — that reached human testing during the period (C022). These differ in composition, dose, route and kinetics, and the ledger keeps them apart (drift check D10).

Two became medicines in the window. Dronabinol was approved by the US FDA on 31 May 1985 for chemotherapy nausea refractory to conventional antiemetics, gained an AIDS-anorexia indication in 1992, moved from US Schedule I to II in 1986 and to Schedule III by DEA final rule of 2 July 1999 (C023). Nabilone had human pharmacology published from 1975, was licensed in the United Kingdom in 1982 for hospital-only use in refractory chemotherapy nausea (and is not a UK controlled drug), and was approved by the FDA in 1985 (the FDA’s own record, opened by the verifier); a Canadian approval in the early 1980s is reported but its year is unverified (C024). The UK licence date and the fact that nabilone sits outside UK controlled-drug schedules come from the House of Lords report and were found by the verifier, not by either researcher.

6. The conditions under which the research was done (C025–C029)

The claim that scheduling made cannabis research impossible is not supported in its strong form (C026). The completed controlled trials in §4 were conducted in the United States after Schedule I placement in 1970, and in the United Kingdom research was possible under Home Office licence as of 1998. What the record does show is regulated access with documented constraints. [HOLD] Congressional records from 1969–1974 describe a standardized research-cannabis supply programme at the University of Mississippi from 1968 and federal contracts for synthetic THC, and a 1976 NIDA review lists standardized supply as an enabling development while acknowledging therapeutic pharmacology (C025) — the documents are cited by URL and have not yet been opened at page level, so C025 is held.

Whether the period’s research was “mostly about harms” cannot be answered from the sources found (C027). Federally funded health-effects research existed; so did sustained therapeutic trial programmes. No coded publication or grant dataset supports a ratio, and the one bibliometric study available codes countries and funders, not orientation. A researcher’s figure of “>75% of federal budgets” was withdrawn as an impression.

[HOLD] A special FDA-sponsored Compassionate IND Program provided marijuana cigarettes to seriously ill patients and was closed to new participants in March 1992 — reported from the 1999 IOM report by one reviewer, not yet opened by the verifier; the asserted 1978 start date and the patient counts (27 approved, 13–15 continuing) rest on a participant memoir and secondary accounts and remain unverified (C028). These figures also match the project’s own archive verbatim, which is a reason for more scrutiny, not less.

[HOLD] On the 1972 rescheduling petition, a DEA administrative law judge recommended Schedule II in 1988 and the Administrator denied the petition in a 1989 final order, with a further denial and remand in 1992; marijuana remained in Schedule I through 1999 (C029). The sequence is consistent across both passes and a 2016 Federal Register history; the 1989 order’s text predates online Federal Register coverage and its quoted wording is unverified.

7. Harms research (C030–C033)

The harms literature was as real as the therapeutic one, and it was studying different things. A 15-year follow-up of 45,570 Swedish conscripts (1987) found a relative risk of schizophrenia of 6.0 (95% CI 4.0–8.9) for those reporting cannabis use on more than 50 occasions; the authors called cannabis an independent risk factor, a causal reading the design cannot by itself deliver (C030). Respiratory research distinguished its endpoints: 47–59 days of heavy smoking produced modest but measurable falls in lung function in 28 young men (1976); an 8-year cohort of 394 young adults found tobacco but not marijuana associated with accelerated FEV1 decline (1997); bronchoscopy in 40 subjects found airway inflammation in marijuana as in tobacco smokers (1998) (C031). “Respiratory harm” is three findings, not one. A 1980 study of CBD at 600 mg/day for 5–12 days lowered hexobarbital clearance by 36% in ten subjects — human drug-interaction evidence, at a research exposure, by 1980 (C032). Early claims of chromosome breakage and immune suppression in users (both 1974) were published; the assertion that they were later refuted was not verified in this round (C033).

8. What the official syntheses said (C034–C037)

Three bodies reviewed this evidence at the close of the window, and their conclusions are reported here as theirs. The 1997 WHO report reviewed health effects across organ systems and included a therapeutic-use section and research recommendations (C034). The UK House of Lords committee (1998) judged the evidence insufficient to establish conclusively whether cannabis itself had medical value, stated that chemotherapy nausea was “the only medical indication for which adequate data from controlled clinical trials exist,” and called for urgent trials in MS and chronic pain; it recommended transferring cannabis from Schedule 1 to Schedule 2 so that doctors could prescribe it on a named-patient basis, and on 3 December 1998 the Government told the Lords it was “unable to agree” with that recommendation and would move only when scientific evidence supported the change (C035). [HOLD] The 1999 US Institute of Medicine report concluded that the data indicated potential therapeutic value of cannabinoid drugs for pain, nausea and appetite, called smoked marijuana a crude delivery system, and recommended short-term controlled trials and non-smoked delivery — a characterisation both researchers and the editorial reviewer gave from the text, and which the verifier has three times been unable to open (C036). Earlier bodies — Shafer (1972), Le Dain (1972), the 1982 IOM report, the 1997 NIH workshop — are in the record on one researcher’s account only, unchecked against their texts (C037).

9. Disease modification, and what was not found (C038–C039)

The earliest disease-modification evidence in the window is non-human. In 1975, oral THC, Δ8-THC and cannabinol retarded a mouse lung tumour while CBD did not and THC did not extend survival in a leukaemia model; in 1998, CBD and THC reduced glutamate toxicity in cultured rat neurons by a receptor-independent antioxidant mechanism (C038). No human study of cannabinoid cancer or neurodegenerative disease-modification was identified by either researcher or the verifier. The 1999 patent application often cited as proof of government knowledge rests on the 1998 culture work; a filing asserts utility, not clinical effect, and its 2003 grant belongs to P2.

Areas for which no human study was identified in the documented searches — not a claim that none exists — include cancer and neurodegenerative disease-modification, large or long randomized trials of whole cannabis, paediatric epilepsy, inflammatory bowel disease, PTSD, and opioid substitution (C039).

10. The seven public claims (C040 and the rulings above)

11. What medicine and science actually knew by the end of 1999

Reasonably established in humans, from small controlled trials: that oral THC and nabilone reduce chemotherapy-induced nausea and vomiting relative to placebo and to 1970s comparators, with CNS/psychoactive adverse effects documented — including a roughly doubled side-effect frequency in the nabilone–prochlorperazine trials (C012–C015); that dronabinol increased appetite in the 1995 AIDS-anorexia trial, while the between-group weight difference was not statistically significant (C021); that cannabis/THC acutely lower intraocular pressure as a physiological effect (C017), and that aerosolised THC acutely dilated airways in the small asthma trial (C018); that intravenous THC acutely raised heart rate (C017). Established in molecules and animals, not as treatment evidence: two cannabinoid receptors and two endogenous ligands (C007–C011). Suggested but not established: analgesia in cancer pain, relief of spasticity, and an anticonvulsant effect of CBD — each on a trial of nine to fifteen patients with compromised blinding (C016, C019, C020). Asserted in period sources, but for which this round did not identify traceable supporting evidence: any human disease-modifying effect in cancer or neurodegeneration (C038); a broad “medical cannabis” proven across conditions (C036, C040); the suppression or destruction of specific official reports (C034, Q8).

Acute cognitive and psychomotor effects, which the period certainly studied, carry no P1 ledger claim and are therefore not asserted here.

12. How this evidence was found, and what may be missing

This is not a systematic review and does not claim to be. Both researchers searched PubMed/MEDLINE, PubMed Central, the Cochrane Library, ClinicalTrials.gov (which opened in 2000 and holds a handful of retrospective registrations from the period), government archives (GovInfo, Federal Register, FDA, UK Parliament), and publisher sites, and filed search logs. The verifier re-ran both count queries, resolved every identifier, and ran a completeness probe that found the two 2001 BMJ systematic reviews, the 1977 intravenous-THC study, the 1998 ophthalmology review, and three datums in the House of Lords report — none cited by either researcher. The probe was targeted, not exhaustive.

What is likely under-represented: non-English literature (Brazilian, German, Czech, Soviet-bloc), pre-1975 MEDLINE records that carry no abstract, conference proceedings, and the primary texts of four official commissions that were summarised but not opened. Full text was available for a minority of period papers; most clinical figures here are abstract-level and are capped accordingly.

Held components as of this version (each a part of a mixed claim, not a whole claim): C025 — the 1968 origin, early federal contracts and 1976 NIDA review details (Congressional Record and NIDA PDFs unopened); C028 — the compassionate-IND start date and patient counts, and the verifier’s own read of the IOM passage; C029 — the text of the 1989 order; C036 — the verifier’s own read of the IOM Executive Summary; C037 — the four earlier official bodies; and the full-text subclaims under C006, C016 and C019. Lifted since v0.1 by verifier page checks: C024-US (FDA record), C035 (House of Lords ch. 8 and Lords Hansard 3 Dec 1998). Each will be resolved, or remain open, by logged correction.

13. Handed to P2 (2000–2017) — and what stays with P1

Research threads for P2: standardized whole-plant extracts and their trial programmes; the large MS spasticity trials; modern epilepsy CBD development; the post-1999 resolution of the 1999 patent filing; the growth of cohort studies on psychosis and cognition; the first head-to-head trials of preparations and routes that P1 lacked. The 2001 BMJ reviews are already used here as retrospective sources and are boundary context for P2, not P2 primary evidence.

Unfinished P1 verification — stays with P1, resolved in its audit or carried as explicitly unresolved P1 findings, not transferred: the compassionate-IND start date and patient counts (C028); the four earlier official bodies (C037); the early federal supply documents (C025); the 1989 order’s text (C029); the full-text subclaims under C006, C016, C019.

Ledger coverage: all 40 claims cited. Verifier-found components (C001, C015, C017, C020, C024) and all HOLD components are mandatory targets for the §M10a cross-audit. Plain-English derivatives follow this text and may not simplify its uncertainty.